Vertex Pharmaceuticals Inc. (VRTX) other research news

VRTX's Altus Biologics Inc. subsidiary received a $75,000 Phase I SBIR from the Department of Health and Human Services to apply its Cross-Linked Enzyme Crystals (CLEC) to oxidation/reduction reactions used in industrial processes. ...